Open-Labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT).
Phase of Trial: Phase IV
Latest Information Update: 29 Aug 2011
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Metabolic syndrome
- Focus Biomarker; Therapeutic Use
- Acronyms EFFORT
- Sponsors AstraZeneca
- 07 Apr 2010 Actual patient number (165) added as reported by ClinicalTrials.gov.
- 03 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2009 Planned end date changed from 1 Nov 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.